TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 6 months post-transplantation and in stable clinical condition~* Treatment with ECMPS doses between 720 mg/day and 1440 mg/day or MMF doses between1000 mg/day and 2000 mg/day, divided in two equal doses 12 hours apart and with no dose titrations planned for the duration of the trial~* Ability to independently take medication~* Successfully ingest a Placebo-IEM capsule with no difficulty~Exclusion Criteria:~* Inability to use the mobile phone provided for use in the clinical trial~* Any episodes of acute rejection in the previous 3 months~* Presence of cognitive impairment~* Active alcohol or drug abuse~* History of dysphagia, or inflammatory bowel disease, or gastrointestinal conditions or surgery that has modified the normal luminal flow of the gastrointestinal tract (e.g. Whipple procedure, bariatric surgery or Roux-en-Y)~* Known allergies, including history of skin reactions to patches, that could preclude safe participation in the study Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ECMPS-IEM (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic~* treatment-naïve or have received no more than 3 systemic treatment regimen(s)~* Positive for translocation or inversion events involving the ROS1 gene~* Negative for translocation or inversion events involving the ALK gene~* Patients with brain metastases are eligible if asymptomatic, or if treated, must be neurologically stable for at least 2 weeks and are not taking any contraindicated medications~* Any prior treatment (chemotherapy, radiation \[except for palliative\], or surgery) must have been completed at least 2 weeks prior to initiation of study medication~* At least 1 measurable tumor lesion as per RECIST v1.1~* Female or male, 18 years of age or older~* ECOG performance status 0 to 1~* Adequate organ function~* Signed and dated informed consent~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including completion of the PRO measures~* Agree to use effective contraception during the study period and for at least 90 days after completion of the study treatment~Exclusion Criteria:~* Current treatment on another therapeutic clinical trial~* Prior therapy specifically directed against ALK or ROS1 fusion genes~* Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function, carcinomatous meningitis, or leptomeningeal disease~* known interstitial fibrosis or interstitial lung disease~* myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack within 3 months prior to start of study treatment~* Ongoing cardiac dysrhythmias of NCI CTCAE v4.03 Grade \>/=2, uncontrolled atrial fibrillation of any grade, or QTc \>470 msec~* Pregnant or breast feeding~* Use of drugs or foods that are known potent CYP3A4 inhibitors or inducers~* Use of other anti-cancer drugs including traditional Chinese medicine on the SFDA list~* Evidence of active malignancy within last 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crizotinib (Type: EXPERIMENTAL): Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 10 months of Herceptin treatment for HER2-positive early breast cancer;~* metastatic breast cancer \>=12 months after discontinuation of Herceptin;~* measurable disease.~Exclusion Criteria:~* previous chemotherapy for metastatic breast cancer;~* brain metastases;~* invasive malignancy other than metastatic breast cancer.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab Monotherapy (Type: ACTIVE_COMPARATOR): Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose on Day 1, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.
- Trastuzumab, Taxane (Type: EXPERIMENTAL): Participant received an initial loading dose of 4 mg/kg trastuzumab i.v. on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death; and concomitant taxane, which is either 100 milligrams per square meter (mg/m2) docetaxel i.v. every 3 weeks, or 75 mg/m2 weekly or 175 mg/m2 every 3 weeks paclitaxel for at least 18 weeks, or more at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Neprilysin on Glucagon-like Peptide-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* men~* body mass index between 20-25~Exclusion Criteria:~* acute diseases within the two weeks~* chronic diseases~* smoker~* alcoholism, drug addiction or recent weight loss~* blood donation within the last 3 months

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): No treatment. Participants are subjected to a standardized meal
- Entrestro as single dose (Type: ACTIVE_COMPARATOR): 194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
- Sitagliptin as single dose (Type: ACTIVE_COMPARATOR): 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
- Entrestro + sitagliptin as single dose (Type: ACTIVE_COMPARATOR): 194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histology confirmed diagnosis of extremities high grade osteosarcoma~* Age ≤ 40 years~* Localized disease or presence of skip metastasis~* Hepatic, renal and bone marrow normal function~* LVEF \> 50%~* No previous surgery and/ or chemotheraputic osteosarcoma treatments,~* No more than 4 weeks interval between histological diagnosis and start of chemotherapy~* Informed consent to the study participation obtained.~Exclusion Criteria:~* Presence of metastases other than skip metastases~* Periosteal Osteosarcoma, parostal osteosarcoma, secondary osteosarcoma,~* Medical contra-indication to the drugs foreseen in the protocol,~* Subject is pregnant or breast feeding~* Mental or social conditions that can compromise a correct adherence to the protocol and its procedures

- Gender: ALL
- Minimum Age: None
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Mifamurtide arm (Type: EXPERIMENTAL): Chemotherapy for patients who over express ABCB1/P-glycoprotein (methotrexate, cisplatinum, doxorubicine, ifosfamide + mifamurtide)
- 3 drugs arm (Type: OTHER): High grade osteosarcoma treatment for patients who do not over express ABCB1/P-glycoprotein

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Anti CD20 in Pemphigus Desease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age\>18~* pemphigus corticoresistant~* pemphigus cortico dependant~* contre-indications : systémic steroids~Exclusion Criteria:~* age \< 18~* cardiopathie~* pregnant woman~* absence contraception~* no consentment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Clinical stage I/II melanoma patients, planned to undergo a sentinel lymph node biopsy (SNB)~* ECOG performance status 0 or 1~* White blood count (WBC) ≥ 3 x10\^9/L~* Platelet count ≥ 100 x10\^9/L~* Hemoglobin ≥ 6.5 mmol/L~* Serum creatinine ≤ 2.5 x ULN~* Total serum bilirubin, AST, ALT and LDH ≤ 2x ULN~Exclusion Criteria:~* Non-oncology vaccine therapy used for prevention of infectious diseases (up-to) 4 weeks prior and/r 8 weeks after any dose of tremelimumab~* Prior treatment with a CD137 agonist or CTLA-4 inhibitor or agonist~* Uncontrolled infectious disease including negative testing for HIV, HBV, HCV~* Autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tremelimumab (Type: EXPERIMENTAL): Intradermal injection of tremelimumab at the primary melanoma excision site, 7 days prior to sentinel node biopsy (SNB), with escalating doses of 2, 5, 10 or 20 mg tremelimumab (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* At least 18 years old at screening and body weight \> 45 kg at screening~* Diagnosed with oHCM consistent with current ACCF/AHA 2011 and meet their recommendations for invasive therapies~* Referred or under active consideration within the past 12 months for SRT procedure and willing to have SRT procedure~* Has documented left ventricular ejection fraction (LVEF) ≥ 60% at Screening~* Has documented oxygen saturation at rest ≥ 90% at Screening~Key Exclusion Criteria:~* Persistent or permanent atrial fibrillation and subject not on anticoagulation for ≥ 4 weeks prior to screening and/or not adequately rate controlled ≤ 6 months prior to screening~* Previously treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \[ASA\])~* For individuals on beta blockers, calcium channel blockers, or disopyramide, any dose adjustment of these medications \< 14 days prior to screening or an anticipated change in regimen during the first 16 weeks of the study~* Any medical condition that precludes upright exercise stress testing~* Paroxysmal, intermittent atrial fibrillation with atrial fibrillation present at screening~* Prior treatment with cardiotoxic agents, such as doxorubicin or similar~* Has a history or evidence of any other clinically significant disorder, condition, or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug: Mavacamten (Type: EXPERIMENTAL): Mavacamten Capsules~Other names:~MYK-461
- Drug: Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo Capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects and Mechanisms of Specific Trunk Exercises in Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a history of chronic LBP with or without recurrences for a minimum of 12 months~* between 21 - 55 years of age~* able to stand and walk without assistance~* have an Oswestry Disability Score of 19% or higher~Exclusion Criteria:~* any major structural spinal deformity including scoliosis, kyphosis, or stenosis~* spinal fracture or dislocation~* osteoporosis~* ankylosing spondylitis~* rheumatoid arthritis~* disc herniation with corroborating clinical signs and symptoms~* serious spinal complications such as tumor or infection~* previous spinal surgery~* frank neurological loss, i.e., weakness and sensory loss~* pain or paresthesia below the knee~* etiology of LBP other than the lumbar spine, e.g., hip joint~* history of neurological disease which required hospitalization~* active treatment for cancer~* history of unresolved cancer~* pregnancy or less than 6 months post-partum or less than 6 months post weaning~* magnified symptom-behavior~* worker's compensation or disability case~* in litigation for the LBP problem~* have a BMI ≥ 30

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Stabilization (Type: EXPERIMENTAL): None
- Strengthening and Conditioning (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women are eligible to participate if they are 40 years or older and have been menopausal (had no menstrual bleeding during the past 12 months)~Exclusion Criteria:~* History of bilateral mastectomy, osteoporosis or renal impairment.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Letrozole, Breast enhancement, Safety (Type: EXPERIMENTAL): Single arm of healthy postmenopausal women who received baseline diagnostic MRI will receive letrozole of 12.5 mg/day orally for three successive days. A second post treatment breast MRI is done right after receiving the three days of letrozole treatment and within one month after the first MRI .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Abdominal Distension by Biofeedback - a Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: episodes of visible abdominal distension triggered by meal ingestion~Exclusion Criteria: organic cause detected by clinical work-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biofeedback (Type: ACTIVE_COMPARATOR): Patients will be taught to control abdominal and diaphragmatic muscles by bio-feedback using EMG recordings.
- Placebo medication (Type: PLACEBO_COMPARATOR): Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a clinical diagnosis of OA or RA and who are expected to require regular anti-inflammatory therapy for arthritis symptom management~* Subjects must be aged 60 years or older with or without a history of gastroduodenal (GD) ulceration; or be of any age 18 years or older and have had documented evidence of GD ulceration 90 days or more prior to the screening visit~Exclusion Criteria:~* Active GD ulceration or GD ulceration within 90 days of the screening visit.~* Concomitant use of low dose aspirin~* Previous MI, stroke or significant vascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assesment of Post-stroke Elbow Flexor Spasticity in Different Forearm Positions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Elbow flexor spasticity~* Grade 1 to 3 spasticity measured with Modified Ashworth Scale~* To agree to participate in the study~Exclusion Criteria:~* \<18 years old~* Pregnancy~* Botulinum toxin injection within the last three months~* Presence of elbow contracture~* History of operation to spastic upper extremity~* Spasticity due to other causes other than stroke~* Do not agree to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Age \>18 years;~* Clear evidence of exposure to one or more war zone trauma events sufficient to satisfy DSM-IV criterion A1 for diagnosis of PTSD;~* DSM-IV diagnosis of PTSD derived from the CAPS; CAPS total score \>50;~* CAPS Recurrent Distressing Dreams item score \>5 (of maximum score of 8);~* stable dose of non-exclusionary medications and psychotherapeutic treatment for at least 4 weeks prior to randomization;~* good general medical health.~* Female participants must agree to use a reliable form of birth control during the study.~Exclusion Criteria~* Psychiatric/Behavioral - meets DSM-IV criteria for current schizophrenia, schizoaffective disorder, psychotic disorder, delirium, or any DSM-IV cognitive disorder; substance dependence disorder within 3 months or any current substance dependence; current cocaine or stimulant abuse; severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior which poses an immediate danger to patient or others.~* Medical - acute or unstable chronic medical illness, including unstable angina, recent myocardial infarction (within 6 months), congestive heart failure, preexisting hypotension or orthostatic hypotension, chronic renal or hepatic failure, pancreatitis, Meniere's disease, benign positional vertigo; narcolepsy, or diagnosed sleep apnea; allergy or previous adverse reaction to prazosin or other alpha-1 antagonist.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- prazosin hydrochloride (Type: ACTIVE_COMPARATOR): prazosin Pfizer Minipress~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose.
- placebo (Type: PLACEBO_COMPARATOR): placebo~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete